title: A new approach to second-line therapy for urothelial cancer?
authors.affiliation: UAB Comprehensive Cancer Center, Birmingham, AL35233, USA. sonpavde@uab.edu
authors.forename: Guru
authors.initials: G
authors.lastname: Sonpavde
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Galsky
authors.forename: Joaquim
authors.initials: J
authors.lastname: Bellmunt
mesh_terms: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D002277:Carcinoma / Q000188:drug therapy*; D004337:Drug Carriers / Q000737:chemistry*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D053758:Nanoparticles; D017239:Paclitaxel / Q000008:administration & dosage*; D014516:Ureteral Neoplasms / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D019459:Urothelium / Q000187:drug effects*
chemical_list: D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D017239:Paclitaxel